Where rash appears in the product information
None of the three documents gives a percentage for rash alone. Each places it inside allergic reactions, and the depth of detail differs by region [1][2][3].
| Document | Entry | Frequency or status |
|---|---|---|
| EU summary of product characteristics, Table 1 and footnote c [2] | Hypersensitivity, a grouped term covering rash and urticaria | Uncommon (up to 1 in 100) |
| EU summary of product characteristics, Table 1 [2] | Anaphylactic reaction | Rare (up to 1 in 1,000) |
| Canadian Product Monograph, sections 8.3 and 8.5 [3] | Hypersensitivity (rash and urticaria) from trial data; anaphylaxis, angioedema, rash and urticaria after approval | Leaflet: uncommon |
| US Prescribing Information, sections 5.7 and 6.2 [1] | Warning on serious hypersensitivity; rash and urticaria among postmarketing reports | No rate |
No injection, no injection-site rash
Injection-site reactions such as redness or itching where the needle went in are a recognised side effect of injectable GLP-1 medicines; a 2026 meta-analysis of randomised trials found them about three and a half times as often as with comparators, while wider skin reactions were infrequent and not significantly increased [6]. A daily tablet removes that category entirely.
One tablet-specific skin effect is easy to confuse with a rash. The EU lists dysaesthesia, an altered skin sensation such as tingling, burning or sensitive skin, as common; it was reported in 2.1% and 5.2% of people on the higher 25 mg and 50 mg strengths used in Europe; the events were mild to moderate, and most people recovered while continuing treatment [2]. Phase 3 trials of the 3, 7 and 14 mg tablets showed no imbalance, though reports have arrived since approval [1][2]. A changed sensation without visible spots is described on our body-aches page; a visible rash is a different matter.
The tablet’s ingredients and the allergy warning
Besides semaglutide, each US Rybelsus® tablet contains magnesium stearate, microcrystalline cellulose, povidone and salcaprozate sodium (SNAC). The Ozempic® tablets described in the same US label contain only magnesium stearate and SNAC [1]. Canada lists the same two ingredient sets for its original 3, 7 and 14 mg tablets and its newer 1.5, 4 and 9 mg tablets [3].
This matters because the contraindication covers the whole tablet: the US label says Rybelsus® must not be used after a serious allergic reaction to semaglutide or to any of its ingredients, and Europe and Canada say the same [1][2][3]. The US label also asks for caution in anyone who has had angioedema or anaphylaxis with another GLP-1 medicine, because it is not known whether they are predisposed to the same with Rybelsus® [1]. If you react to a tablet, the full ingredient list printed in the leaflet is worth bringing to your prescriber or pharmacist.
Antibodies are a separate question. In US trials, 0.5% of people on semaglutide tablets developed anti-semaglutide antibodies, and no clinically significant effect on how the drug behaved in the body was identified [1].
What reporting studies show for the tablets
A 2024 analysis of US FDA reports for semaglutide tablets from 2019 to 2023 found 267 reports in the skin category, fewer than expected compared with all other medicines (reporting odds ratio 0.86), and 33 in the immune category, also below expectation (0.50) [4]. A second 2024 FAERS study that split semaglutide reports by route found that skin events made up 4.57% of oral-semaglutide reports and 3.21% of injection reports [5]. That is a share of the reports received, not a rate in patients; neither study can show that the tablet caused any rash.
Rashes that have nothing to do with Rybelsus®
MedlinePlus notes that most rashes come from skin inflammation and that the cause is often clear from how and where the rash appears [7]. Common causes include:
- Contact dermatitis from soaps, cosmetics, detergents, dyes, latex or plants such as poison ivy.
- Eczema, psoriasis and seborrhoeic dermatitis around the eyebrows, nose or scalp.
- Infections such as impetigo or shingles, which usually affects one side of the body.
- Insect bites, other medicines, and conditions such as lupus.
Gentle care for a mild rash
For a simple rash with no warning signs, MedlinePlus suggests avoiding scrubbing, using a gentle cleanser and warm rather than hot water, patting the skin dry, leaving the area open to the air and stopping any recently added cosmetics or lotions [7]. It adds that 1% hydrocortisone cream and oral antihistamines are available without a prescription and may ease itching; ask a pharmacist whether either suits you alongside your other medicines.
Hives are raised, sometimes itchy red bumps, usually caused by an allergic reaction to a drug or food, and they often fade on their own; rarely they come with swelling in the airway, which is an emergency [8]. Because the Rybelsus® label treats allergic reactions seriously, a new rash or hives soon after starting the tablets is worth reporting to your prescriber the same day, even if it seems mild.
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
The signs and contact information below come from this article’s sourced guidance.
Emergency
- Swelling of the face, lips, tongue or throat, or problems breathing or swallowing
Contact: Emergency services; stop the tablets
Rybelsus® Medication Guide [1]
- Severe rash or itching, fainting, dizziness or a very rapid heartbeat
Contact: Emergency services; stop the tablets
- Hives with wheezing, a tight throat or a hoarse voice
Contact: Emergency services
Today
At your next appointment
- A mild rash that does not improve with gentle care or keeps coming back
Contact: Your health care provider or a dermatologist
MedlinePlus [7]